First Patient Enrolled in RECOVER-AV Trial of AlphaVac F18 System for Treatment of Acute PE - Cardiovascular News

First patient enrolled in RECOVER-AV trial of AlphaVac F18 system for treatment of acute PE - Interventional News

AngioDynamics has announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multicentre, international, single-arm study evaluating the AlphaVac multipurpose mechanical aspiration (MMA) F1885 system in the treatment of acute, intermediate-risk pulmonary embolism (PE). The study follows the US Food and Drug Administration (FDA) 510(k) clearance of the AlphaVac F1885 system for the treatment of PE in the USA in…

First patient enrolled in RECOVER-AV trial of AlphaVac F18 system for treatment of acute PE - Cardiovascular News

AngioDynamics has announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multicentre, international, single-arm study evaluating the AlphaVac multipurpose mechanical aspiration (MMA) F1885 system in the treatment of acute, intermediate-risk pulmonary embolism (PE). The study follows the US Food and Drug Administration (FDA) 510(k) clearance of the AlphaVac F1885 system for the treatment of PE in the USA in…

AngioDynamics Enrolls First Patient in RECOVER-AV Trial of Acute PE - Endovascular Today

June 23, 2025—AngioDynamics, Inc. announced first patient enrollment in the RECOVER-AV clinical trial. The prospective, multicenter, multinational, single-arm study is evaluating the company’s AlphaVac multipurpose mechanical aspiration (MMA) F1885 system in the treatment of acute, intermediate-risk pulmonary embolism (PE). According to AngioDynamics, the RECOVER-AV trial is designed to evaluate the safety and efficacy of the AlphaVac F1885 syst…

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

LATHAM, N.Y.--(BUSINESS WIRE)--Jun 23, 2025-